U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Secondary Central Nervous System Non-Hodgkin Lymphoma

MedGen UID:
857242
•Concept ID:
C3897648
•
Neoplastic Process

Definition

A non-Hodgkin lymphoma that has spread to the central nervous system following the initial presentation in another nodal or extranodal site. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVSecondary Central Nervous System Non-Hodgkin Lymphoma

Professional guidelines

PubMed

Management of secondary central nervous system lymphoma.
Cwynarski K, Cummin T, Osborne W, Lewis J, Chaganti S, Smith J, Linton K, Greaves P, McKay P, Fox CP; British Society for Haematology (BSH) Committee
Br J Haematol 2023 Jan;200(2):160-169. Epub 2022 Nov 21 doi: 10.1111/bjh.18539. PMID: 36408800
Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
Central Nervous System Lymphoma: Approach to Diagnosis and Treatment.
Correia CE, Schaff LR, Grommes C
Cancer J 2020 May/Jun;26(3):241-252. doi: 10.1097/PPO.0000000000000449. PMID: 32496457

Recent clinical studies

Etiology

Central Nervous System Lymphoma.
Shah T, Venur VA
Semin Neurol 2023 Dec;43(6):825-832. Epub 2023 Nov 23 doi: 10.1055/s-0043-1776783. PMID: 37995744
How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP, Nayak L, Cwynarski K
Blood 2023 Nov 23;142(21):1771-1783. doi: 10.1182/blood.2023020168. PMID: 37702537Free PMC Article
CAR T-cell therapy in large B cell lymphoma.
Boardman AP, Salles G
Hematol Oncol 2023 Jun;41 Suppl 1(Suppl 1):112-118. doi: 10.1002/hon.3153. PMID: 37294963Free PMC Article
Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article

Diagnosis

Central Nervous System Lymphoma.
Shah T, Venur VA
Semin Neurol 2023 Dec;43(6):825-832. Epub 2023 Nov 23 doi: 10.1055/s-0043-1776783. PMID: 37995744
Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JEC, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski K; International Extranodal Lymphoma Study Group (IELSG)
Lancet Haematol 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5. PMID: 33513372Free PMC Article
Central Nervous System Lymphoma: Approach to Diagnosis and Treatment.
Correia CE, Schaff LR, Grommes C
Cancer J 2020 May/Jun;26(3):241-252. doi: 10.1097/PPO.0000000000000449. PMID: 32496457
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article

Therapy

How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP, Nayak L, Cwynarski K
Blood 2023 Nov 23;142(21):1771-1783. doi: 10.1182/blood.2023020168. PMID: 37702537Free PMC Article
CAR T-cell therapy in large B cell lymphoma.
Boardman AP, Salles G
Hematol Oncol 2023 Jun;41 Suppl 1(Suppl 1):112-118. doi: 10.1002/hon.3153. PMID: 37294963Free PMC Article
Management of secondary central nervous system lymphoma.
Cwynarski K, Cummin T, Osborne W, Lewis J, Chaganti S, Smith J, Linton K, Greaves P, McKay P, Fox CP; British Society for Haematology (BSH) Committee
Br J Haematol 2023 Jan;200(2):160-169. Epub 2022 Nov 21 doi: 10.1111/bjh.18539. PMID: 36408800
Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
Central Nervous System Lymphoma.
Chukwueke UN, Nayak L
Hematol Oncol Clin North Am 2019 Aug;33(4):597-611. Epub 2019 May 10 doi: 10.1016/j.hoc.2019.03.008. PMID: 31229157

Prognosis

Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
Roschewski M, Hodson DJ
Haematologica 2024 Feb 1;109(2):388-400. doi: 10.3324/haematol.2021.278613. PMID: 37706315Free PMC Article
Central Nervous System Lymphoma.
Shah T, Venur VA
Semin Neurol 2023 Dec;43(6):825-832. Epub 2023 Nov 23 doi: 10.1055/s-0043-1776783. PMID: 37995744
How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP, Nayak L, Cwynarski K
Blood 2023 Nov 23;142(21):1771-1783. doi: 10.1182/blood.2023020168. PMID: 37702537Free PMC Article
Central Nervous System Lymphoma.
Chukwueke UN, Nayak L
Hematol Oncol Clin North Am 2019 Aug;33(4):597-611. Epub 2019 May 10 doi: 10.1016/j.hoc.2019.03.008. PMID: 31229157
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article

Clinical prediction guides

How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP, Nayak L, Cwynarski K
Blood 2023 Nov 23;142(21):1771-1783. doi: 10.1182/blood.2023020168. PMID: 37702537Free PMC Article
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735Free PMC Article
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS
JAMA Oncol 2021 Jul 1;7(7):993-1003. doi: 10.1001/jamaoncol.2021.1074. PMID: 33956047Free PMC Article
Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, Vitolo U
Expert Rev Hematol 2019 Sep;12(9):787-796. Epub 2019 Aug 8 doi: 10.1080/17474086.2019.1643232. PMID: 31305170
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article

Recent systematic reviews

Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N, Masood A, Dhaliwal A, Khurana S, Davis J, Hashmi H, Husnain M
Clin Lymphoma Myeloma Leuk 2023 Jan;23(1):15-21. Epub 2022 Oct 7 doi: 10.1016/j.clml.2022.09.008. PMID: 36328891
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735Free PMC Article
Movement disorders in primary central nervous system lymphoma: two unreported cases and a review of literature.
Grillo P, DI Giuliano F, Massa R, Mercuri NB, Schirinzi T
Neurol Sci 2021 Mar;42(3):905-910. Epub 2021 Jan 14 doi: 10.1007/s10072-020-04985-3. PMID: 33443666
Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.
Fletcher CD, Kahl BS
Leuk Lymphoma 2014 Oct;55(10):2228-40. Epub 2014 Feb 24 doi: 10.3109/10428194.2013.869326. PMID: 24286262
Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature.
Colocci N, Glantz M, Recht L
Semin Neurol 2004 Dec;24(4):395-404. doi: 10.1055/s-2004-861534. PMID: 15637651

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...